Cleerly Showcases Cutting-Edge AI Innovations in Cardiovascular Imaging at RSNA 2024

Cleerly at RSNA 2024: Revolutionizing Cardiovascular Imaging

Cleerly, a trailblazer in advanced cardiovascular imaging, is set to unveil its groundbreaking AI-enabled innovations at the Radiological Society of North America (RSNA) Conference 2024, held from December 1 to 5 at McCormick Place Convention Center, Chicago. With a commitment to precision in healthcare, Cleerly will demonstrate its advanced coronary computed tomography angiography (CCTA) system that offers personalized diagnosis and treatment options for coronary artery disease (CAD).

Exploring AI-Enabled Solutions

At the heart of Cleerly's advancements is its AI-powered digital care platform, designed specifically for healthcare professionals. The technology leverages non-invasive CCTA imaging to accurately identify and characterize heart disease, enabling doctors to provide tailored treatment plans. Cleerly’s ability to perform sub-millimeter quantification of atherosclerosis allows for better assessment of plaque buildup within coronary arteries, enhancing the care continuum for patients.

Cleerly's AI-Quantitative Coronary CT (AI-QCT) has undergone multiple comparative studies with invasive gold standards, showcasing remarkable accuracy in detecting the presence, extent, and composition of coronary atherosclerosis. Furthermore, Cleerly ISCHEMIA, an additional product in their AI lineup, demonstrates superior diagnostic performance compared to traditional tests such as nuclear SPECT imaging, illustrating Cleerly's role at the forefront of cardiac diagnostics.

Engaging with Industry Leaders

Attendees are encouraged to visit Cleerly's booth #3905 to engage with the company’s leadership and view live demonstrations of these innovative technologies. A special session is scheduled for December 2, from 2:30 PM to 3:30 PM, where healthcare professionals has the chance to interact with the experts behind Cleerly's advancements. Participants can look forward to thought-provoking discussions focused on the future of health technology and improving patient outcomes, all while enjoying health-conscious refreshments.

Recent Advancements in Coverage

In a significant boost for the adoption of AI technologies in healthcare, Cleerly recently achieved regulatory milestones for its AI-QCT scans, now approved for coverage by five Medicare Administrative Contractors. This new coverage, effective as of November 24, 2024, applies to patients presenting stable or acute symptoms of CAD, marking a pivotal moment for the integration of AI in cardiovascular diagnostics. Approximately 93 million Medicare beneficiaries will have access to Cleerly Labs' Plaque Analysis, underscoring the increasing recognition of AI's impact on detailed medical imaging and patient care.

Additionally, the American Medical Association has officially granted a permanent CPT Category I code for Cleerly's AI-QCT methods, set to take effect on January 1, 2026. This advancement reflects the growing significance of advanced imaging technology in the standard healthcare practice.

Cleerly’s Mission

Cleerly is on a vital mission to reduce heart attack occurrences through advanced care standards in heart disease diagnosis. By harnessing cutting-edge strategies along with FDA-cleared solutions driven by artificial intelligence, Cleerly aims to enhance the understanding and management of coronary artery disease. Their mission is underscored by a scientific foundation built on analyzing millions of medical images, combined with a talented team of clinical and technological experts striving to improve health literacy within the cardiovascular care landscape.

To learn more about Cleerly and its pioneering technologies, please visit Cleerly's website or stop by Booth 3905 located in South Hall A, Level 3 during the conference.

This year's RSNA is not only an opportunity to witness advancements in imaging but also a chance to reimagine patient care driven by innovative technology. Join Cleerly on this transformative journey as it pushes boundaries in cardiovascular imaging and personalization of heart disease management.